Martin Dietrich, MD, PhD

Articles

Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?

September 19th 2023

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Adagrasib for Patients with KRAS G12C–Mutant NSCLC

September 12th 2023

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC

September 12th 2023

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

NSCLC With Uncommon EGFR Mutations: First-Generation EGFR TKIs and Role of Immunotherapy

September 5th 2023

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations

September 5th 2023

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

Treatment Options for Patients with NSCLC with EGFR Mutations

August 29th 2023

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Strategies to Improve Biomarker Testing in NSCLC

August 29th 2023

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC

August 22nd 2023

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

NSCLC: Biomarker Testing Strategies and Turnaround Time

August 22nd 2023

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

Liquid vs Tissue Biopsies in NSCLC

August 15th 2023

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

Biomarker Testing in Non-Small Cell Lung Cancer

August 15th 2023

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

Exploring TROP2 Expression in Patients with NSCLC

June 16th 2023

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.

Targeting HER3 in EGFR-Mutant NSCLC

June 16th 2023

Experts review data on treatment with HER3-directed agents in NSCLC for patients with EGFR mutations.

HER2-Directed Agents in NSCLC

June 9th 2023

Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.

Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer

June 9th 2023

Martin Dietrich, MD, PhD, details the molecular target CEACAM5 and its use in the treatment of patients with non-small cell lung cancer.

ADCs in Development for the Treatment of Lung Cancer

June 2nd 2023

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Overview of Antibody Drug Conjugates in Lung Cancer

June 2nd 2023

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.

Emerging Concepts on the Role of Immunotherapy in NSCLC

February 20th 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.

Future Perspectives in Biomarker Testing and Targeted Therapy in NSCLC

February 13th 2023

Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.

NSCLC: Discussing Molecular Biomarkers and Treatment Decisions with Patients

February 13th 2023

Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.